Effect of vasoactive intestinal peptide on gastric adenocarcinoma

Li, Guohua; Qian, Wei; Song, Gengqing; Hou, Xiaohua

doi:10.1111/j.1440-1746.2007.04947.x

Cited by 7 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include pheochromocytomas[63, 165], gastric-cancer[166, 167•], cervical-cancer[168], choriocarcinoma-cells[169], neuroendocrine-tumors[60•, 62, 170] and renal-cancer[59, 171•, 172]. …”

Section: Vip/pacap: Other Tumorsmentioning

confidence: 99%

Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer

Moody¹,

Nuche-Berenguer

Jensen

2016

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of review To summarize the roles of VIP/PACAP and their receptors(VPAC1, VPAC2/PAC1) in human tumors as well as their role in potential novel treatments. Recent findings Considerable progress has been made in understanding of the effects of VIP/PACAP on growth of various tumors as well as in the signaling cascades involved, especially of the role of transactivation of the Epidermal growth factor(EGF) family. The overexpression of VPAC1/2, PAC1 on a number of common neoplasms (breast, lung, prostate, CNS, neuroblastoma) is receiving increased attention both as a means of tumor imaging the location and extent of these tumors, as well as for targeted directed treatment, by coupling cytotoxic agents to VIP/PACAP analogues. Summary VIP/PACAP has prominent growth effects on a number of common neoplasms, which frequently overexpressed the three subtypes of their receptors. The increased understanding of their signaling cascades, effect on tumor growth/differentiation, and the use of the overexpression of these receptors for localization/targeted cytotoxic delivery, are all suggesting possible novel tumor treatments.

show abstract

Section: Vip/pacap: Other Tumorsmentioning

confidence: 99%

Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer

Moody¹,

Nuche-Berenguer

Jensen

2016

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

show abstract

“…Many studies showed that VIP was related with the gastric cancer [10, 18, 20]. We had showed that some gastric cancer cells in tumor tissues could secrete VIP [10].…”

Section: Discussionmentioning

confidence: 99%

“…We had showed that some gastric cancer cells in tumor tissues could secrete VIP [10]. The physiological functions of VIP in the GI tract were associated with the secretion and motor of the digestive system.…”

Section: Discussionmentioning

confidence: 99%

“…Hejna et al reported that the serum VIP concentration increased in patients with gastric cancer [18]. We have showed that the gastric adenocarcinoma tissues contained secreting VIP cancer cells [10]. Above, this suggested that VIP might play an important role in inhibiting organism immune functions.…”

Section: Introductionmentioning

confidence: 96%

“…The gastrointestinal hormone vasoactive intestinal peptide (VIP) belongs to the secretin/VIP family, which was initially isolated from the intestine [7] and secreted by neurons, endocrine cells, immune cells [8, 9], and gastric carcinoma cells [10]. VIP affect not only gastrointestinal functions but also organism immune functions through binding to G protein-coupled receptors [11], which are distributed in most human tissues [12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Vasoactive Intestinal Peptide (VIP) on NKG2D Signal Pathway and Its Contribution to Immune Escape of MKN45 Cells

Wang

Zhou

et al. 2013

The Scientific World Journal

Self Cite

View full text Add to dashboard Cite

Objective. To investigate VIP effect on the cytotoxicity of NK cell to gastric cancer cells in vitro and the relation between the effect with the NKG2D signal molecules in NK cells. Material and Methods. NK cells were purified from peripheral blood mononuclear cells (PBMC). Before and after NK cells were incubated with VIP or its antagonist (D-p-Cl-Phe6,Leu17)-VIP, we detected the cytotoxicity of NK cells to MKN45 gastric cancer cells by MTT and detected the expressions of NKG2D, DAP10, and NF-κB proteins and mRNAs in NK cells by immunocytochemistry and RT-PCR in those conditions. Then we analyzed the effect of VIP and its antagonist on the cytotocicity of NK cell to gastric cancer cells and on expressions of NKG2D, DAP10, and NF-κB signal molecules in NK cells. Results. VIP could inhibit the cytotoxicity of NK cells to MKN45 cells and could inhibit the expressions of NKG2D, DAP10, and NF-κB in NK cells. However, (D-p-Cl-Phe6, Leu17)-VIP could reverse those effects. Conclusions. The VIP inhibited the cytotoxicity of NK cell to MKN45 cells which might get through inhibiting the expressions of NKG2D signal molecules in NK cells. This may be one mechanism of gastric cancer cells escaping organism immune clearance.

show abstract

Vasoactive Intestinal Peptide Promotes Immune Escape of MKN45 Cells by Inhibiting Antigen-Presenting Molecules of Dendritic Cells In Vitro

Zhou

Jiang

et al. 2016

Int J Pept Res Ther

View full text Add to dashboard Cite

Effect of vasoactive intestinal peptide on gastric adenocarcinoma

Cited by 7 publications

References 27 publications

Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer

Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer

Effect of Vasoactive Intestinal Peptide (VIP) on NKG2D Signal Pathway and Its Contribution to Immune Escape of MKN45 Cells

Vasoactive Intestinal Peptide Promotes Immune Escape of MKN45 Cells by Inhibiting Antigen-Presenting Molecules of Dendritic Cells In Vitro

Contact Info

Product

Resources

About